Business Wire2d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Physician's Weekly5d
Renal-Limited TMA After Allo-HSCT With Membranous Nephropathy
The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...
Business Wire27d
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
A biologics license application (BLA) is pending before the FDA for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).